PL1860101T3 - Sól winianu izofagominy i sposoby zastosowania - Google Patents

Sól winianu izofagominy i sposoby zastosowania

Info

Publication number
PL1860101T3
PL1860101T3 PL07252109T PL07252109T PL1860101T3 PL 1860101 T3 PL1860101 T3 PL 1860101T3 PL 07252109 T PL07252109 T PL 07252109T PL 07252109 T PL07252109 T PL 07252109T PL 1860101 T3 PL1860101 T3 PL 1860101T3
Authority
PL
Poland
Prior art keywords
isofagomine
tartrate
sale
methods
salt
Prior art date
Application number
PL07252109T
Other languages
English (en)
Inventor
Benjamin Mugrage
David Palling
Kamlesh A Sheth
Philip J Rybczynski
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of PL1860101T3 publication Critical patent/PL1860101T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
PL07252109T 2006-05-24 2007-05-23 Sól winianu izofagominy i sposoby zastosowania PL1860101T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80802006P 2006-05-24 2006-05-24
US89071907P 2007-02-20 2007-02-20
EP07252109A EP1860101B1 (en) 2006-05-24 2007-05-23 Tartrate sale of isofagomine and methods of use

Publications (1)

Publication Number Publication Date
PL1860101T3 true PL1860101T3 (pl) 2011-10-31

Family

ID=38462442

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07252109T PL1860101T3 (pl) 2006-05-24 2007-05-23 Sól winianu izofagominy i sposoby zastosowania

Country Status (14)

Country Link
US (2) US7501439B2 (pl)
EP (1) EP1860101B1 (pl)
JP (1) JP5292605B2 (pl)
AT (1) ATE504570T1 (pl)
AU (1) AU2007202359B2 (pl)
BR (1) BRPI0706114A2 (pl)
CA (1) CA2590122C (pl)
DE (1) DE602007013648D1 (pl)
DK (1) DK1860101T3 (pl)
IL (1) IL183415A (pl)
MX (1) MX2007006175A (pl)
PL (1) PL1860101T3 (pl)
PT (1) PT1860101E (pl)
WO (1) WO2007140212A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
PT2040548E (pt) 2006-06-23 2012-08-02 Amicus Therapeutics Inc Método para o tratamento de distúrbios neurológicos através do aumento da atividade da -glucocerebrosidase
CN104530068B (zh) 2007-05-22 2017-05-03 阿米库斯治疗学公司 用于制备异法戈明的化合物
PL2252313T3 (pl) 2008-02-12 2015-09-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
JP2012508740A (ja) * 2008-11-14 2012-04-12 パーキンソンズ インスティテュート 変性α−シヌクレイン機能の治療のための組成物および方法
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
CA2778349C (en) * 2009-10-19 2018-12-04 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
EP3143875B1 (en) 2009-10-19 2020-05-27 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
EP2723384B1 (en) * 2011-06-22 2018-08-29 The General Hospital Corporation Treatment of proteinopathies
WO2013112706A1 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
EP2831043B1 (en) 2012-03-27 2022-07-27 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
AU2013240187A1 (en) 2012-03-28 2014-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Salicylic acid derivatives useful as glucocerebrosidase activators
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
DE102017103346A1 (de) * 2017-02-17 2018-08-23 Lts Lohmann Therapie-Systeme Ag Strukturierte orodispergierbare Filme
CN111278439A (zh) * 2017-10-26 2020-06-12 夏尔人类遗传性治疗公司 包含葡萄糖脑苷脂酶和异烟肼的调配物
WO2020006269A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP7561632B2 (ja) 2018-06-27 2024-10-04 キネタ, インコーポレイテッド プロテアソーム活性増強化合物
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
CN113906012A (zh) * 2019-04-25 2022-01-07 武田药品工业有限公司 异法戈明盐、使用方法和调配物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A

Also Published As

Publication number Publication date
EP1860101B1 (en) 2011-04-06
JP2007314540A (ja) 2007-12-06
EP1860101A1 (en) 2007-11-28
JP5292605B2 (ja) 2013-09-18
WO2007140212A3 (en) 2008-12-24
BRPI0706114A2 (pt) 2008-11-18
US7501439B2 (en) 2009-03-10
US7863453B2 (en) 2011-01-04
MX2007006175A (es) 2009-02-16
US20070281975A1 (en) 2007-12-06
IL183415A0 (en) 2007-09-20
IL183415A (en) 2012-03-29
DE602007013648D1 (de) 2011-05-19
CA2590122C (en) 2015-03-31
WO2007140212A2 (en) 2007-12-06
PT1860101E (pt) 2011-07-12
US20090176830A1 (en) 2009-07-09
AU2007202359B2 (en) 2012-02-16
ATE504570T1 (de) 2011-04-15
CA2590122A1 (en) 2007-11-24
DK1860101T3 (da) 2011-07-25
AU2007202359A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
PL1860101T3 (pl) Sól winianu izofagominy i sposoby zastosowania
EA200702208A1 (ru) Ингибиторы дипептидилпептидазы-iv
IL210577A (en) Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation
ATE530519T1 (de) Cyclobutylaminderivate
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
PL1617834T3 (pl) Kompozycja farmaceutyczna zawierająca mleczan i jej zastosowania
BRPI0415164A (pt) dispositivo para administrar uma composição bioterapêutica, composição bioterapêutica, método de preparação de uma composição bioterapêutica, método de tratamento, e dispensador
UA97122C2 (ru) Кристаллическая форма миндальной кислоты как ингибитор тромбина (варианты)
GB0510196D0 (en) Composition for treatment of a detached retina and method of production thereof
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
DE602006013271D1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
UA94042C2 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
IL184383A0 (en) A pharmaceutical composition for the treatment of lysosomal storage disorder, a method for the manufacture thereof and a kit containing the same
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE602007010926D1 (de) Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol
HU0500975D0 (en) Process for producing of extract of sour cherry seed, use of extract for producing of medicament and medicaments consist extract
PT1720867E (pt) Processo para a preparação de ziprasidona
NO20063617L (no) Diarylmetylidenpiperidinderivater, fremstilling og anvendelse derav
MD3395G2 (ro) Metodă de recoltare a probelor de sânge de la animalele de laborator